Nexalin's Brazilian Clinical Trial Wins Young Researcher Award at BRAIN 2026
Event summary
- Dr. Victor Fontenelle Bastos de Lima received the Young Researcher Award at BRAIN 2026 for research evaluating Nexalin’s DIFS™ platform.
- The study focused on insomnia symptoms in patients with comorbid anxiety, showing significant and durable improvement in sleep quality.
- Nexalin has received ANVISA approval to market its Nexalin SYNC device in Brazil for anxiety, depression, and insomnia.
- The award-winning research is based on a clinical trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo.
The big picture
Nexalin's recognition at BRAIN 2026 underscores the growing scientific validation of its non-invasive neurostimulation technology. The award highlights the potential of the DIFS™ platform to address interconnected neuropsychiatric domains, positioning Nexalin as a differentiated player in the mental health technology space. This development comes as the company prepares for product launch in Brazil, where it has already secured regulatory approval.
What we're watching
- Regulatory Pathway
- Whether Nexalin can leverage this award to accelerate its FDA De Novo regulatory pathway in the U.S.
- Market Expansion
- The pace at which Nexalin can commercialize its technology in Brazil and other international markets.
- Clinical Validation
- How additional clinical data from the HALO™ Clarity pivotal program will support the broader applicability of the DIFS™ platform.
Related topics